Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00009-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ascogu25&_hsenc=p2ANqtz-9jZ0RwZCLYRQD1SzJ0z-T3QoKpVxJRGC1o6jnZMjyDmayh4eWq5kGPV00jd9xnHaAfzB7Tt6AAPZzGAwVs01L8gj8DRA&_hsmi=347179969&utm_content=347179969&utm_source=hs_email February 13, 2025 News Call to prioritise access to essential cancer medicines in Latin America and the Caribbean Talha Burki https://www.thelancet.com/journals/lanonc/onlinefirst The Lancet Group's global events Conferences https://www.thelancet.com/events/conferences?dgcid=hubspot_email_conferencealerts_ascogu25&specialty=oncology&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8XtF_YP3g4AxhMYrpNpTj486sJCcbgKv9v7N4HRJKTbZ8Qd-ne4vWvj8Hqm7XH4Ads74b9f8auC6_9m7pXz6pdPukThg&_hsmi=347179969&utm_content=347179969&utm_source=hs_email